Alkermes to Host Webcast with Panel of Oncology Experts to Discuss Nemvaleukin Alfa Data Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

DUBLIN, May 28, 2021 / PRNewswire / – Alkermes plc (Nasdaq: ALKS) announced today that it will host a webcast and conference call at 4:00 p.m. ET (9:00 p.m. BST) at Friday June 4, 2021 to review data updates presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting of the Company’s ARTISTRY-1 and ARTISTRY-2 clinical trials evaluating the nemvaleukin alfa (nemvaleukin) candidate for immuno- oncology. The company will provide an overview of the data presented, followed by a panel discussion with expert oncologists and researchers from the ARTISTRY clinical program, Valentina boni, MD, Ph.D., medical oncologist and principal investigator, START Madrid at the Centro Integral Oncológico Clara Campal; and Omid Hamid, MD, chief of research and immunotherapy, The Angeles Clinic and Research Institute.

Investor and analyst webcast with expert oncologists
Date and time: Friday, June 4, 2021 at 4 p.m. ET (9:00 p.m. BST)
Compose: +1 877-407-2988 for US callers and +1 201-389-0923 for international callers.
Investors and analysts can also view slides and listen to the live audio webcast of the presentation on the Investors section of the Alkermes website at A replay of the webcast will be archived on the company’s website for 30 days after the presentation.

Nemvaleukin poster presentations at ASCO

Abstract: 2513
Title: ARTISTRY-1: Nemvaleukin Alfa as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Valentina boni, MD, Ph.D., medical oncologist and principal investigator, START Madrid at the Centro Integral Oncológico Clara Campal, Madrid, Spain
Date / time of presentation: The on-demand poster discussion session will take place on June 4, 2021 at 9:00 a.m.ET.

Abstract: 2552
Title: Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2
Presenter: Omid Hamid, MD, Head of Research and Immuno-Oncology, The Angeles Clinic and Research Institute
Date of presentation: The poster presentation will be available on request for participants from June 4, 2021.

About Nemvaleukin alfa (“nemvaleukin”)
Nemvaleukin is an innovative and experimental fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while simultaneously avoiding the activation of immunosuppressive cells by preferring binding to the IL-2 receptor complex of intermediate affinity. The selectivity of nemvaleukin is designed to take advantage of the proven anti-tumor effects of existing IL-2 therapy while alleviating some limitations.

About the ARTISTRY Clinical Development Program
ARTISTRY is an Alkermes sponsored clinical development program evaluating nemvaleukin alfa as a potential cancer immunotherapy. The ARTISTRY program includes multiple clinical trials evaluating intravenous and subcutaneous administration of nemvaleukin, both as monotherapy and in combination with anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTIST-1, ARTIST-2, ARTIST-3 and ARTIST-6.

About Alkermes plc
Alkermes plc is a fully integrated global biopharmaceutical company developing innovative drugs in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, as well as a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Alkermes contacts:
For investors: Sandy Coombs, +1 781 609 6377
For media: Sourojit Bhowmick, Ph.D. +1 781 609 6397

SOURCE Alkermes plc

Related links

Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

Arthur Muir and Tsang Yin-hung return unharmed after becoming America’s oldest woman and fastest on Everest

KATHMANDU, Nepal – A retired Chicago lawyer who became the oldest American to climb Mount …

Leave a Reply

Your email address will not be published. Required fields are marked *